Supriya Lifescience was incorporated on March 26, 2008. The company has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic and has been consistent exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India
| Bidding Dates |
|---|
| 16 Dec 2021 - 20 Dec 2021 |
| Subscription |
|---|
| 71.51x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,796 | 1 | 13 | 54 | 25.5 M | ₹265 - ₹274 | 68.26 % | ₹6770.1 M - ₹7000.0 M | RHP DOC |
Supriya Lifescience IPO SUBSCRIPTION STATUS
20 Dec '21Supriya Lifescience IPO overall subscription rate was 71.51 times the total available shares
Supriya Lifescience IPO retail subscription rate was 56.01 times in the retail segment
Supriya Lifescience IPO non-institutional investor subscription rate was 161.22 times in the non-institutional investor category
Supriya Lifescience IPO Qualified Institutional Bidder subscription rate was 31.83 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 10% | 15% | 75% |
20 Dec 2021 (Day 3) | 56.01x | 161.22x | 31.83x |
17 Dec 2021 (Day 2) | 25.38x | 2.9x | 0.53x |
16 Dec 2021 (Day 1) | 25.38x | 2.9x | 0.53x |
Supriya Lifescience FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from operations (Rs in millions) | Cash Flow from operations (Rs in millions) | Free Cash flow (Rs in millions) | Margins |
| H1FY22 | 659.6 | 2,248.0 | 158.5 | -388.1 | 42.9% |
| FY21 | 1,238.3 | 3,853.7 | 799.3 | 316.9 | 45.0% |
| FY20 | 734.0 | 3,116.4 | 1,160.6 | 915.4 | 33.9% |
| FY19 | 394.2 | 2,778.4 | 486.7 | 418.0 | 25.5% |
Supriya Lifescience IPO SUBSCRIPTION STATUS DETAILS
Supriya Lifescience had 25.5 M shares on offer
Supriya Lifescience IPO offer price was in the range ₹265 - ₹274
Supriya Lifescience IPO minimum Investment was ₹14796
Supriya Lifescience IPO issue size was ₹ 6770.1 M - ₹ 7000.0 M
Supriya Lifescience had a minimum lot size of 54 Shares per application
Supriya Lifescience NUMBER OF SHARES ON OFFER
Supriya Lifescience IPO IMPORTANT DATES
| Issue Open Date | 16 Dec 2021 |
| Issue close Date | 20 Dec 2021 |
| Allotment Date | 23 Dec 2021 |
| Refund Date | 24 Dec 2021 |
| Demat Account Credit Date | 27 Dec 2021 |
| Listing Date | 28 Dec 2021 |
| Listing on Exchange(s) | NSE and BSE |
| Supriya Lifescience Allotment Status | Exchange |
Supriya Lifescience IPO subscription opened on 16 Dec 2021, and closed on 20 Dec 2021
IPO allotment for Supriya Lifescience was finalized on Thursday, 23 Dec 2021
IPO listing for Supriya Lifescience was on NSE and BSE on Tuesday, 28 Dec 2021
Supriya Lifescience IPO LISTING GAINS
| Issue Price (adjusted) | 274.0 |
| Listing Open Price | 425.0 |
| Listing Close Price | 390.4 |
| Listing Gain% | 55.1% |
| Current Gain% | 237.0% |
Supriya Lifescience Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supriya Lifescience Ltd. | 923.4 | 7432.2 | 35.5 | 3.2 | 9 | 17.4 | 15.4 | 839.4 | 18.8 | 209.1 | 11.3 | 26 | 11.3 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Supriya Lifescience INFORMATION ON IPO ISSUE
About Supriya Lifescience
Supriya Lifescience was incorporated on March 26, 2008. The company has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic and has been consistent exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India
Object of the Issue
1. Funding capital expenditure requirements of the company
2. Repayment and/ or pre-payment, in full or part, of certain borrowings availed by the company and
3. General corporate purposes
Supriya Lifescience - PROMOTERS
| Name |
|---|
| Satish Waman Wagh |
Supriya Lifescience Book Running Lead Managers
ICICI Securities Limited
supriya.ipo@icicisecurities.com
Axis Capital Limited
sll.ipo@axiscap.in
Supriya Lifescience Registrar to the Offer
Link Intime India Private Limited
supriyalife.ipo@linkintime.co.in
Supriya Lifescience Strengths
Significant scale with a leadership position across key & niche products
Backward integrated business model
Geographically diversified revenues with a global presence across 86 countries
Advanced manufacturing and research and development capabilities
Consistent strong financial performance due to de-risked business model
Supriya Lifescience Risks
The company derives a significant portion of the revenue from the sale of certain products and few customers
The company has not entered into definitive agreements to use the proceeds of the Fresh Issue
The company depends to a large extent on third-party suppliers and transporter
Lenders have imposed certain restrictive conditions on the company under our financing arrangements.
IPO FAQs
This IPO consists of an offer for sale of up to Rs 500.0 crore, of 18,248,175 shares. It also consists of a fresh issue of Rs 200.0 crore.
The promoter of the company is Satish Waman Wagh.
The category allocation of qualified institutional buyers is 75.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 10.0%.
The price band of the IPO is Rs 265.0 - 274.0.
The IPO application opens on Dec 16, 2021 and closes on Dec 20, 2021.
The minimum lot size for the IPO is 54. The maximum lot size for the IPO is 702.
For all category investors, the minimum application amount for this IPO is Rs. 14,796.0, the maximum value for this IPO is Rs 192,348.0.
This IPO will be allotted on Dec 23, 2021.
The refund will be credited to your account on Dec 24, 2021.
The allotted shares will be credited to your demat on Dec 27, 2021.
Supriya Lifescience Ltd.’s shares listed on the stock exchanges on Dec 28, 2021.